Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer:a series of 20 cases

查看全文 作　　者：Qi [1]Zheng;Yu [1]Yao;Kejun [1]Nan

机构地区：[1]Department of Medical Oneology,the First Affiliated Hospital,Xi'an Jiaotong University,Xi'an,Shaanxi 710061,China.

出　　处：《The Journal of Biomedical Research》索引2012年第26卷第3期,共6页

摘　　要：The purpose of this study was to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel as a rescue regimen in the treatment of patients with advanced non-small-cell lung cancer.We retrospectively reviewed the medical records of 20 patients with stage IV non-small-cell lung cancer.The patients had progressive disease after standard antitumor therapy and subsequently received intravenous albumin-bound paclitaxel at the dose of 100 mg/m2 in weekly schedule.Cumulative findings showed that the overall response rate was 30.0%,the disease control rate amounted to 40%,and the 1 year survival rate was 30%.In addition,the median time to progression and the median survival time reached 5 and 10 months,respectively.Meanwhile,no severe hypersensitivity reactions and grade 4 adverse effects were reported.In summary,weekly-administered albumin-bound paclitaxel seems to be an effective and safe regimen for elderly patients with stage IV non-small-cell lung cancer who were refractory to conventional therapy. 关键词：非小细胞肺癌静脉注射紫杉醇白蛋白患者老年纳米抗肿瘤治疗

相关文献

参考文献（36）
引证文献（7）
耦合文献（0）

参考文献(36)

引证文献(7)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer:a series of 20 cases

参考文献(36)

引证文献(7)

用户提示